Gina Chapman, CARGO Therapeutics president and CEO
CARGO Therapeutics heads to Nasdaq in first CAR-T cell therapy IPO pitch of 2023
A cancer cell therapy biotech that emerged just nine months ago with $200 million and a Phase I trial already underway will test the public …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
